Printer Friendly

Sepracor awarded patent for R-ondasentron, its eleventh U.S. patent for an improved form of an FDA-approved drug; Patent reinforces Sepracor's proprietary position in pharmaceutical marketplace.

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Dec. 14, 1995--Sepracor Inc., (NASDAQ: SEPR), today announced that it has been granted its eleventh U.S. patent for an Improved Chemical Entity (ICE ), an improved form of an FDA-approved drug. The patent, No. 5,470,868, covers the use of R-ondansetron as an antiemetic.

Marketed by Glaxo Wellcome as Zofran, racemic ondansetron is a leading antiemetic used to treat nausea and vomiting associated with chemotherapy treatments and surgery. Sepracor estimates that emesis occurs in 70 percent of the 3.6 million chemotherapy episodes and 30 percent of the 23 million surgical procedures performed in the U.S. each year. The sales of Zofran in 1994 were approximately $600 million.

Despite its effectiveness for emesis, racemic ondansetron has shown a meaningful incidence of adverse side effects such as tachycardia, angina and electrocardiographic alterations, including second-degree heart block which is most prevalent in nonchemotherapy uses. Sepracor believes that the single isomer of ondansetron provides an opportunity for development of a safer, more effective antiemetic.

"This patent reinforces our proprietary position in the pharmaceutical marketplace and furthers our strategy to develop safer, purer and more effective versions of already popular and proven therapeutics," said Timothy J. Barberich, Sepracor's President and Chief Executive Officer. "R-ondansetron shows the potential to become an effective antiemetic with a significantly improved cardiovascular side-effect profile over racemic ondansetron."

Sepracor's preclinical trials have indicated that R-ondansetron has superior antiemetic activity compared with the racemic product, while S-ondansetron causes cardiovascular side effects.

Sepracor develops Improved Chemical Entities (ICE) that are enhanced forms of existing, widely sold pharmaceuticals. ICEs can be developed at significantly less cost, time and risk than New Chemical Entities (NCEs), thus providing a pipeline of new product opportunities with significant market potential. -0-

Zofran is a registered trademark of Glaxo Wellcome plc.

CONTACT: David P. Southwell

Chief Financial Officer

Sepracor Inc.


Jean M. Devine

Director, Investor Relations

Sepracor Inc.

(508) 481-6700
COPYRIGHT 1995 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1995, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 14, 1995
Previous Article:StarSight Telecast Announces Proposed Agreement with THOMSON multimedia.
Next Article:Montgomery Securities Initiates Coverage of Gliatech, Inc. with a BUY Rating.

Related Articles
Sepracor awarded U.S. patent for R-albuterol, a single-isomer form of FDA-approved albuterol.
Sepracor awarded U.S. patent for terfenadine carboxylate; Triggers $7.5 million in milestone payments, future royalties.
Sepracor awarded its twelfth U.S. patent for improved form of an FDA-approved drug; Granted patent for purified form of itraconazole, a drug for...
Sepracor announces receipt of three U.S. patents for improved forms of FDA-approved drugs; Patents cover improved urinary incontinence, BPH and...
Sepracor awarded U.S. patent for descarboethoxyloratadine (DCL), an active metabolite of Claritin.
DUSA Pharmaceuticals Sues Physicians For Infringement of its Levulan'R' Photodynamic Therapy Patents.
Sepracor Receives Notice of Second Abbreviated New Drug Application Submission for Levalbuterol Hydrochloride Inhalation Solution.
NovaDel Issued Second Canadian Patent for Oral Spray Delivery of Major Classes of Pharmaceuticals.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters